We are live on ! Find out more
CLRBW

Cellectar Biosciences, Inc.

Delisted

CLRBW was delisted on the 20th of August, 2019.

2 hedge funds and large institutions have $201K invested in Cellectar Biosciences, Inc. in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% less capital invested

Capital invested by funds: $248K → $201K (-$47K)

50% less funds holding

Funds holding: 42 (-2)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-2
Holders Change %
-50%
% of All Funds
0.05%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
1
Closed
2
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$392
Name Holding Trade Value Shares
Change
Change in
Stake
SM
1
Sabby Management
Florida
$188K -$392 -1,225 -0.5%
CAM
2
Cormorant Asset Management
Massachusetts
$13K

CLRBW Hedge Fund Activity: Q3 2016 in Review

2 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences, Inc. (CLRBW) for Q3 2016, worth a combined $201K — down 19% from $248K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of CLRBW and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Sabby Management, cutting an estimated $392.

  • 2 institutional investors held Cellectar Biosciences, Inc. (CLRBW) as of Q3 2016, down from 4 in Q2 2016.
  • Funds reported $201K of Cellectar Biosciences, Inc. stock for Q3 2016, down 19% quarter-over-quarter.
  • 0 funds opened new Cellectar Biosciences, Inc. positions in Q3 2016 and 2 closed out, a net change of -2 holders.
  • The largest Cellectar Biosciences, Inc. seller in Q3 2016 was Sabby Management, an estimated $392 sold.

Based on aggregated 13F filings for Q3 2016.